NMSG is an independent Nordic organization of research active MDs and Norwegian, Swedish, Icelandic, Finnish, Estonian, Lithuanian, and Danish clinics / hospitals who conduct clinical myeloma research.

About 60 haematological clinics / hospitals - among these 25 university hospitals - from Norway, Sweden, Iceland, Finland and Denmark are part of NMSG. In addition to this clinics from Estonia and Lithuania participate in some of the clinical trials.

The vision of NMSG is to ensure optimal evidence-based treatment of all myeloma patients in the Nordic countries through e.g. population-based clinical and controlled studies with associated basic research on the biology of the disease.

NMSG works for this vision by

  • Conducting comprehensive Phase III trials including all aspects of the myeloma disease with focus on life quality of the patients.
  • Conducting Phase II trials in well characterized patient groups supported by lab research.
  • Establishing a knowledge network about the myeloma disease and the treatment thereof for clinically working MDs, nurses, myeloma patients and their relatives.

For more information about the NMSG organization, please look under NMSG organization in the menu.